January 22, 2018 5:00pm

STML closed up +$0.70 to $14.25 and is down -$0.45 or -3.16% to $13.80

Stemline Therapeutics (STML) intends to offer and sell, subject to market conditions, 3,7 M shares in an  offering.

STML intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering.


No details on pricing … yet

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.